Summit Therapeutics Inc. SMMT
At closeNov 9, 2026, 6:49 PM EST
After hours · Nov 9, 6:49 PM ET
- YTD
- +2.00%
- 1 year
- -1.87%
- Market cap
- 14.27B
- EPS (ttm)
- -1.06
- Shares out
- 799.76M
- Forward P/E
- -17.26
- YTD return
- +2.00%
- 1-year return
- -1.87%
- Volume
- 7.24M
- Avg volume
- 6.23M
- Open
- 16.36
- Previous close
- 16.33
- Day's range
- 15.82 – 18.15
- 52-week range
- 12.07 – 29.23
- Beta
- -1.52
- Analysts
- Buy
- Price target
- 30.02 (+68.3%)
- Earnings date
- Feb 22, 2027
5D +2.69 (+17.59%)
Key statistics
- Enterprise value
- 12.45B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 25.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -213.92M
- Total cash
- 629.79M
- Total debt
- 19.98M
- Return on equity
- -220.01%
- Short % of float
- 25.81%
- 50-day average
- 16.25
- 200-day average
- 16.14
Analyst view
Consensus: buy
- Target (low)
- 11.96
- Target (mean)
- 30.02
- Target (high)
- 42.93
- Strong buy1
- Buy10
- Hold6
- Sell0
- Strong sell0
Next earnings
Feb 22, 2027
Expected Feb 22, 2027. Consensus EPS estimate -0.2076.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 22, 2027 | Dec 30, 2026 | -0.36 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.28174 | -0.26 | +0.02 | +7.72% |
| Jul 23, 2026 | Jun 30, 2026 | -0.27439 | -0.28 | -0.01 | -2.04% |
| Apr 30, 2026 | Mar 31, 2026 | -0.33 | -0.24 | +0.09 | +27.27% |
| Feb 23, 2026 | Dec 31, 2025 | -0.10264 | -0.29 | -0.19 | -182.54% |
| Oct 20, 2025 | Sep 30, 2025 | -0.17577 | -0.31 | -0.13 | -76.37% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Sep 29, 2026 | Citigroup | main | Buy | Buy |
| Sep 23, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Sep 9, 2026 | Jefferies | up | Hold | Buy |
| Aug 26, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 25, 2026 | Bernstein | up | Underperform | Market Perform |
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- smmttx.com
News
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? 
SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus 
Summit Therapeutics Q3 Adj. EPS $(0.20) Beats $(0.28) Estimate 
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 
Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday 
Summit Therapeutics Announces Clinical Trial Collaboration With The ECOG-ACRIN Cancer Research Group To Evaluate Ivonescimab In A Phase II/III Study In Biliary Tract Cancer 
Chip Stocks Slide as South Korea's KOSPI Plunges, J&J Sinks 6%: Stock Market Today 
10 Health Care Stocks With Whale Alerts In Today’s Session 
Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7% 
Amazon, Alphabet, Tesla Stock Rises: Robinhood Traders Sell Anyway
Your note
Sign in to keep a note on SMMT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANAND BHASKAR | Officer | Stock Award(Grant) | Oct 7, 2026 | 261,047 |
| DUGGAN ROBERT WILLIAM | Chief Executive Officer | Purchase | Jun 11, 2026 | 610,016,000 |
| SONI MANMEET SINGH | Chief Operating Officer | Purchase | Jun 3, 2026 | 3,123,600 |
| XIA YU | Director | Purchase | Oct 20, 2025 | 0 |
| ZANGANEH MAHKAM | Chief Executive Officer | Purchase | Jun 11, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 4.10% | 32,786,348 | 584.91M | Jun 29, 2026 |
| FMR, LLC | 1.26% | 10,043,947 | 179.18M | Jun 29, 2026 |
| State Street Corporation | 1.19% | 9,536,796 | 170.14M | Jun 29, 2026 |
| Blackrock Inc. | 1.19% | 9,529,041 | 170.00M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 0.72% | 5,734,484 | 102.30M | Jun 29, 2026 |
| UBS Group AG | 0.65% | 5,233,798 | 93.37M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.46% | 3,707,548 | 66.14M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 0.45% | 3,635,145 | 64.85M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.33% | 2,667,317 | 47.58M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.32% | 2,531,231 | 45.16M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.26% | 2,047,862 | 36.53M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.22% | 1,778,361 | 31.73M | Jun 29, 2026 |